Quantro Therapeutics GmbH, a Vienna, Austria-based provider of a transcriptomic drug discovery and R&D platform targeting transcription factors, received a 12-month, non-dilutive research grant from the Austrian Research Promotion Agency (FFG).
The amount of the deal was not disclosed.
The company intends to use the funds to support the development of ASCEND, its AI-driven medicinal chemistry platform, accelerating its drug discovery pipeline and establishing versatile workflows for the optimization of small molecule modulators and degraders.
Led by CEO Michael Bauer, Quantro Therapeutics focuses on building a pipeline of modulators, inhibitors, and degraders of transcription factors and gene expression regulators. Its proprietary platform uses time-resolved gene expression profiling technology to target transcription factors involved in cancer and other therapeutic disorders, such as inflammation.
Don’t just read the news. Own the data. Stop manually tracking deals. Access this round and over 100 others this week—in our structured Master Database (XML) + Weekly Intelligence PDF. 👉 [Access FinSMEs Intelligence Hub]
FinSMEs
04/11/2026